Clinical trials
PAH clinical trials
Below are recruiting pah clinical trials, each written for real people, not researchers. We’re tracking 53 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06274801RecruitingPhase 3
Long-term study of seralutinib for pulmonary arterial hypertension
This trial is for people with pulmonary arterial hypertension (PAH) who have already completed a previous study of the drug seralutinib. It offers continued access to the treatment so doctors can watch its safety and effects over a longer time.
Fresno, CaliforniaAges 18–75 - NCT06649110RecruitingPhase 1/Phase 2
A study of LTP001 for healthy people and those with PAH
This study tests an investigational medicine called LTP001 for pulmonary arterial hypertension (PAH). Part A checks safety in healthy volunteers, and Part B tests if it helps people with PAH by improving blood flow in the lungs.
Scottsdale, ArizonaAges 18–100 - NCT07713914RecruitingPhase 4
Triple therapy vs sildenafil dose increase for PAH
This study compares two approaches for people with PAH whose current treatment (a combination of sildenafil and an endothelin receptor antagonist) needs to be stepped up. Half the participants will add a third medicine (iloprost or selexipag), while the other half will increase their sildenafil dose. The goal is to see which strategy works better for improving symptoms and lowering risk.
São Paulo, São PauloAges 18 years+ - NCT04062565RecruitingPhase 3
Testing treprostinil plus riociguat for advanced pulmonary artery hypertension
This study tests whether taking injected treprostinil together with riociguat can improve how the heart and lung blood vessels work in people with advanced pulmonary artery hypertension (PAH). It may help improve blood-flow measurements and the structure of the heart.
Tucson, ArizonaAges 18 years+ - NCT05452889RecruitingEarly Phase 1
PET scan study in pulmonary hypertension related to scleroderma
This early study uses a PET scan (a type of imaging test) to better understand lung blood-vessel disease in people who have pulmonary hypertension related to scleroderma. It may help researchers find how imaging signals relate to disease and risk.
Pittsburgh, PennsylvaniaAges 18–75 - NCT05462574Recruiting
MRI study of heart fat in pulmonary arterial hypertension
This trial uses MRI (and an additional MRI measurement called MRS) to study fat in the right side of the heart in people with pulmonary arterial hypertension (PAH). It may help researchers understand what’s going on in PAH and how it relates to symptoms and exercise ability.
Nashville, TennesseeAges 18 years+ - NCT05464095Recruiting
Mobile health support for pulmonary arterial hypertension
This study tests whether using a mobile health tool can help people with pulmonary arterial hypertension (PAH) manage their condition in daily life. It’s aimed at adults who are stable on their PAH medicines and can track activity using a wearable device.
Nashville, TennesseeAges 18 years+ - NCT05587712RecruitingPhase 2
Sotatercept trial for children with pulmonary arterial hypertension
This Phase 2 trial tests sotatercept, a medicine that targets the blood-vessel changes in pulmonary arterial hypertension (PAH), in children. It may help improve how well the heart and lungs work by changing the underlying disease process.
Los Angeles, CaliforniaAges 1–17 - NCT05745961Recruiting
Measuring a lung protein in pulmonary artery hypertension
This study measures how much of a specific lung protein (TSPO) is present in people with pulmonary artery hypertension. The results may help researchers better understand the disease and guide future treatments.
LondonAges 25–75 - NCT06104228RecruitingPhase 2
Xenon MRI to detect and track pulmonary hypertension
This trial uses a special MRI scan (using xenon gas) to see how well the lungs are working in people with pulmonary arterial hypertension (PAH). It aims to improve diagnosis and monitoring of PAH from connective tissue disease or unknown cause.
Durham, North CarolinaAges 18–75 - NCT06317805RecruitingPhase 4
Three-medicine start vs. two oral pills for new PAH
This study compares starting treatment with three medicines, including a continuous infusion (treprostinil), versus two oral medicines for people newly diagnosed with moderate-to-high risk pulmonary arterial hypertension (PAH). The goal is to see which approach improves heart function and symptoms more effectively.
LinzAges 18–70 - NCT06350032RecruitingPhase 3
Testing treprostinil safety in children with PAH
This trial tests a medicine called treprostinil in children with severe pulmonary arterial hypertension (high blood pressure in the lungs). The study aims to see if it is safe and tolerable for kids who need this kind of therapy.
Vienna, State of ViennaAges Up to 18 years - NCT06567379Recruiting
Heart function study in pulmonary arterial hypertension
This trial uses special ultrasound imaging to look at how well the heart works in people newly diagnosed with pulmonary arterial hypertension (PAH). It aims to understand heart changes before and after starting PAH treatment.
NancyAges 19 years+ - NCT06658522RecruitingPhase 4
Sotatercept for right heart function in pulmonary hypertension
This study tests a medicine called sotatercept to see if it can improve how the right side of your heart pumps in people with PAH. It may help you feel better and slow down the disease.
Amsterdam, North HollandAges 18–70 - NCT06865118Recruiting
Home management of heart issues in scleroderma
This study tests whether people with systemic sclerosis (scleroderma) and pulmonary arterial hypertension (PAH) can safely monitor their heart health at home using a smartphone or other internet-connected device. If you have PAH and are comfortable using technology, this trial may help make care more convenient.
OsloAges 18 years+ - NCT06872112RecruitingPhase 1
Artesunate for pulmonary arterial hypertension safety study
This trial tests if artesunate, a malaria drug, is safe and tolerable for people with pulmonary arterial hypertension (PAH). It may offer a new treatment option for PAH patients whose symptoms persist despite using two or more standard therapies.
Stanford, CaliforniaAges 18–60 - NCT06917196Recruiting
Inhaled imatinib for advanced lung disease before or after transplant
This trial tests whether a special inhaled form of the medicine imatinib can help people with advanced lung scarring or high blood pressure in the lungs. It is designed for those who are on the path to a lung transplant or already received one.
Pavia, PaviaAges 18 years+ - NCT06947473RecruitingPhase 1/Phase 2
CAR T-cell therapy for lupus, sclerosis, and Sjogren's
This trial tests a new type of immune cell therapy (CAR T-cells from umbilical cord blood) for people with certain autoimmune diseases that haven't responded to standard treatments. It aims to see if targeting two proteins (CD19 and BCMA) can help calm the overactive immune system.
Beijing, Beijing MunicipalityAges 6–65 - NCT07039604Recruiting
Real-world study of PADN for pulmonary artery hypertension
This study tracks how well a procedure called PADN works for people with pulmonary artery hypertension (PAH) in real-life medical settings. PADN is a minimally invasive treatment that targets nerves around the lungs to help lower blood pressure in the arteries.
Nanjing, JiangsuAges Any age - NCT07217522Recruiting
Genetics of pulmonary hypertension study
This study looks at the genes that may be linked to pulmonary hypertension. By providing a saliva sample and filling out a health survey from home, you can help researchers learn more about this condition.
Piscataway, New JerseyAges 18 years+ - NCT07236970Recruiting
AI screening for pulmonary hypertension in scleroderma
This study uses artificial intelligence to find better ways to screen for pulmonary arterial hypertension (a type of high blood pressure in the lungs) in people with systemic sclerosis (scleroderma). The goal is to catch the condition earlier so treatment can start sooner.
Granada, AndalusiaAges 18–80 - NCT07356778RecruitingPhase 4
Study of sotatercept for Eisenmenger syndrome patients
This trial tests a new drug called sotatercept for people with Eisenmenger syndrome or a related heart defect that hasn't been repaired. It may help if current treatments aren't working well enough.
Fukuoka, Not Required For This CountryAges 18 years+ - NCT07365332RecruitingPhase 3
IKT-001 for pulmonary arterial hypertension
This study tests a new medicine called IKT-001 for people with pulmonary arterial hypertension (PAH). It aims to see if IKT-001 helps improve exercise ability and other symptoms when added to current PAH therapies.
Louisville, KentuckyAges 18–75 - NCT01347216Recruiting
COMPERA study for lung vessel pressure medicines
This study follows people with different types of high blood pressure in the lungs (pulmonary hypertension) to see how starting specific lung blood vessel medicines affects outcomes. It may help improve how clinicians choose and monitor treatment over time.
LeuvenAges 1 week+
Hear when a new PAH trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for pah?
- Yes. Clin2 currently lists 53 recruiting pah studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a pah trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a pah trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.